TARO News and Press, Taro Pharmaceutical Industries Ltd. From 02/14/22

The healthcare industry is growing rapidly amid increasing demand from an aging population and digital transformation in health systems and technologies, among other factors. And because clinical innovation is expected to continue in the healthcare sector this year, we think it could be profi...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and nine months ended December 31, 2021. Quarter ended December 31, 2021 Highlights ─ compared to December 31, 2...

The coronavirus pandemic has accelerated innovations and the adoption of advanced technologies in the healthcare sector. Moreover, national healthcare spending in the United States has increased significantly. The healthcare market is growing and shows promising prospects. Healthcare stocks F...

Taro Pharmaceutical Industries (NYSE:TARO) appoints William J. Coote as Vice President, CFO and Chief Accounting Officer, effective today. Most recently, Mr. Coote has held progressively responsible positions with a variety of global companies such as Bowne & Co. Prude...

Bad news for Apple and Amazon turned into good news for Microsoft (NASDAQ:MSFT) on Friday. While two of the software giant's megacap rivals suffered earnings-inspired declines, MSFT rose to a new 52-week high and took the crown as the world's largest company by market cap. Want to hear someth...

Taro Pharmaceutical (NYSE:TARO): Q3 GAAP EPS of $0.66 misses by $0.36. Revenue of $132M (-7.6% Y/Y) misses by $21.23M. Press Release For further details see: Taro Pharmaceutical EPS misses by $0.36, misses on revenue

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and six months ended September 30, 2021. Quarter ended September 30, 2021 Highlights ─ compared to September 30,...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2021, after the close of market on Thursday, October 28, 2021. The release will be accessible on Taro’s website a...

Taro Pharmaceutical (TARO): Q2 Non-GAAP EPS of $1.09 beats by $0.25; GAAP EPS of -$0.50 misses by $1.34.Revenue of $147.1M (+25.1% Y/Y) beats by $9.87M.Settlements and loss contingencies of $60.0 million reflect an additional legal contingency provision related to ongoing multi-jurisdiction c...

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2021, after the close of market on Tuesday, July 27, 2021. The release will be accessible on Taro’s website at www.taro.com . ...